'
In this month’s Letter to Investors we discuss how the bond-driven bloodbath in share markets is throwing up some of the best valuation opportunities that we’ve seen in global small caps for years.
By Andrew Mitchell & Steven Ng Co-founders and Senior Portfolio Managers
In this month’s Investment Strategy Note we discuss the relationship between interest rates and share prices and why it’s more complicated than you think.
In this month’s Letter to Investors we analyse the impact that ripping bond yields has had specifically on small caps and how not all parts of the small cap market have been treated equally.
In this month’s Investment Strategy Note we ‘weigh in’ with our view on the impact that GLP-1 drugs, such as Ozempic for diabetes and Wegovy for weight loss, could have on Resmed’s share price and why overall we are happy to maintain the company as a core position in the Ophir High Conviction Fund (ASX:OPH).
Subscribe to receive our latest insights, including market insights, stock commentary and fund performance direct to your inbox.
All information shared is kept in strict confidence, as outlined in Ophir’s Privacy Policy.
Please note the following information has been prepared for the use of Wholesale and Professional Investors only.
By clicking Agree, you are confirming you are an Australian Wholesale Investor as defined by section 761G of the Corporations Act 2001.